Literature DB >> 17488959

Use of alendronate after 5 years of treatment.

Juan Erviti, Javier Gorricho.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17488959     DOI： 10.1001/jama.297.18.1979-a

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.

Authors:  Kuntheavy Ing-Lorenzini; Jules Desmeules; Olivier Plachta; Domizio Suva; Pierre Dayer; Robin Peter
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

2.  Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women.

Authors:  Monika A Izano; Romain Neugebauer; Bruce Ettinger; Rita Hui; Malini Chandra; Annette L Adams; Fang Niu; Susan M Ott; Joan C Lo
Journal:  J Manag Care Spec Pharm       Date:  2019-06

3.  Determinants of Oral Bisphosphonate Use Beyond 5 Years.

Authors:  Monika A Izano; Joan C Lo; Bruce Ettinger; Susan M Ott; Bonnie H Li; Fang Niu; Rita L Hui; Romain Neugebauer; Annette L Adams
Journal:  J Manag Care Spec Pharm       Date:  2020-02

4.  Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study.

Authors:  Juan Erviti; Alvaro Alonso; Javier Gorricho; Antonio López
Journal:  BMJ Open       Date:  2013-02-20       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.